Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding

Recruiting Observational Study
ARDS ARDS Disease Progression
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
246 (estimated)
Sponsor
Institut de Recerca Biomèdica de Lleida · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
COVID-19 resulted in the largest cohort of critical illness survivors in history, heightened awareness of the importance of the respiratory sequelae after an acute distress respiratory syndrome (ADRS). Despite the advancement of acute-phase ARDS management, it is unknown whether there are differences in the longitudinal recovery trajectories between patients with post-ARDS due to COVID-19 and due …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male and female patients aged ≥18 years * Admission to the ICU * Diagnosis of severe pneumonia and/or diagnosis of acute respiratory distress syndrome (ARDS) based on the 2023 definition due to any origin (infectious and non-infectious) Exclusion Criteria: * Life expectancy …
Contacts

Jessica González Gutiérrez, MD, PhD

973 70 53 72

jgonzalezgutierrez88@gmail.com

CONTACT

Ferran Barbé Illa, MD, PhD

973 70 53 72

febarbe.lleida.ics@gencat.cat

CONTACT